Alnylam Pharmaceuticals Inc. (ALNY) has filed a Clinical Trial Application with the U.K. Medicines and Healthcare products Regulatory Agency to initiate a phase 1/2 clinical trial with ALN-AAT for the treatment of AAT deficiency-associated liver disease (alpha-1 liver disease).